Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Drug Distribution: Volume of Distribution01:25

Drug Distribution: Volume of Distribution

5.2K
The volume of distribution refers to the theoretical volume necessary to contain the entire amount of an administered drug at the same concentration observed in the blood plasma. The body's intracellular fluid compartment, which makes up two-thirds of the total body water, is contrasted with the extracellular fluid compartment—comprising plasma and interstitial fluid—that accounts for one-third. The volume of distribution can vary depending on the characteristics of the drug.
5.2K
Volume of Distribution01:20

Volume of Distribution

247
The apparent volume of distribution (Vd) is a crucial pharmacokinetic parameter representing the hypothetical body fluid volume into which a drug disperses. It is calculated based on the total amount of drug in the body (estimated from the administered dose and bioavailability) divided by the plasma drug concentration. The total amount of drug in the body does not directly refer to the dose given but is derived by accounting for absorption, distribution, metabolism, and excretion processes.
247
Drug Binding to Blood Components01:30

Drug Binding to Blood Components

175
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
175
Factors Affecting Drug Distribution: Physiological Barriers01:23

Factors Affecting Drug Distribution: Physiological Barriers

254
Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
254

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differentiation of cord blood-derived Innate Lymphoid Cells 1  into KIR+NKG2A- natural killer cells in a human stem cell niche.

Stem cells translational medicine·2026
Same author

A single-cell transcriptional reference for the functional and developmental diversity of neonatal innate lymphoid cells.

Cell reports·2026
Same author

Unifying Summary Statistic Selection for Approximate Bayesian Computation.

Statistics and computing·2026
Same author

Non-linear association of coagulation factor XI with mortality.

Med (New York, N.Y.)·2025
Same author

A binary prototype for time-series surveillance and intervention.

Epidemics·2025
Same author

Platelet-activating histone/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome.

Blood advances·2025
Same journal

Profilin-1 as a Potential Biomarker in Acute Ischemic Stroke: Predictive Value for Large Vessel Occlusion and Mechanical Thrombectomy.

Clinical laboratory·2026
Same journal

Soluble Thrombomodulin can Predict In-Hospital Mortality of Community-Acquired Pneumonia Patients in Intensive Care Unit.

Clinical laboratory·2026
Same journal

Cytomegalovirus Seroprevalence in Morocco - a 10-Year Single-Center Study.

Clinical laboratory·2026
Same journal

Impact of Inactivated SARS-CoV-2 Vaccines on Serum Glycan Profiles and Protein N-Glycosylation.

Clinical laboratory·2026
Same journal

Albumin Concentration Associates Linearly with Unfavorable Outcomes at Three Months Post-Acute Ischemic Stroke in Koreans.

Clinical laboratory·2026
Same journal

Prognostic Value of the Blood Urea Nitrogen-to-Albumin Ratio for ICU Mortality in Cardiogenic Shock Patients: Evidence from the MIMIC-IV Database.

Clinical laboratory·2026
See all related articles

Related Experiment Video

Updated: Jul 23, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.3K

Gender-Associated Variation in DOAC Levels.

Anja Moldenhauer, Peter Hellstern, Till Hoffmann

    Clinical Laboratory
    |July 12, 2023
    PubMed
    Summary
    This summary is machine-generated.

    Peak direct oral anticoagulant (DOAC) levels vary significantly by age and gender, particularly for rivaroxaban. Incorporating age and gender into DOAC reference ranges may improve dosing accuracy for patients on these anticoagulants.

    More Related Videos

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
    08:09

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

    Published on: June 7, 2018

    9.8K
    Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
    08:42

    Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

    Published on: October 22, 2014

    27.4K

    Related Experiment Videos

    Last Updated: Jul 23, 2025

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
    08:13

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

    Published on: September 30, 2021

    6.3K
    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
    08:09

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

    Published on: June 7, 2018

    9.8K
    Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
    08:42

    Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

    Published on: October 22, 2014

    27.4K

    Area of Science:

    • Pharmacology
    • Clinical Medicine
    • Hematology

    Background:

    • Direct oral anticoagulants (DOACs) like rivaroxaban and apixaban are increasingly used for venous thromboembolism (VTE) prophylaxis and treatment, often replacing Vitamin K antagonists.
    • Accurate DOAC plasma level measurement is crucial for dose adjustments in specific clinical scenarios.
    • Significant inter-individual fluctuations in peak and trough DOAC levels complicate treatment decisions due to overlapping reference ranges.

    Purpose of the Study:

    • To investigate whether peak and trough DOAC plasma levels can be more precisely defined by considering patient age and gender.
    • To determine if age and gender influence rivaroxaban and apixaban concentrations.

    Main Methods:

    • Collected peak and trough anti-Xa concentrations from patients treated with rivaroxaban (n=93) or apixaban (n=51).
    • Analyzed 83 rivaroxaban and 49 apixaban samples after excluding those with uncertain oral intake.
    • Compared concentrations between males and females, and between patients younger than 60 and older than 60 years using Student's t-test and regression analysis.

    Main Results:

    • No significant age or gender differences were observed for apixaban peak levels.
    • Women exhibited significantly higher peak rivaroxaban concentrations compared to men (308.8 vs. 206.4 ng/mL, p=0.013).
    • Patients over 60 years old had significantly higher peak rivaroxaban levels than younger patients (293.7 vs. 211.7 ng/mL, p=1.29 x 10⁻⁸).

    Conclusions:

    • Significant age-related differences in peak rivaroxaban levels were identified, suggesting age should inform reference ranges.
    • Gender-associated differences in rivaroxaban levels were observed, potentially explaining associated hypermenorrhea.
    • Incorporating both age and gender into the determination of peak blood concentration references for DOACs is recommended.